ReviewCurrent treatment options in allergy2014
Allergen-Specific Immunotherapy in Asthma.
Review in Current treatment options in allergy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Sublingual immunotherapy for asthma.The Cochrane database of systematic reviews · 2020Pooled it
- Sublingual immunotherapy for asthma.The Cochrane database of systematic reviews · 2015Pooled it
- Sustained Clinical Improvement in Birch Pollen Allergy After Two Pre-Seasonal Short Courses of Allergen-Specific Immunotherapy: A Long-Term Open-Label Extension Study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Trial
- Liver-targeted allergen immunotherapy rapidly and safely induces antigen-specific tolerance to treat allergic airway disease in mice.Science translational medicine · 2025Article
- Nanomaterials for antigen-specific immune tolerance therapy.Drug delivery and translational research · 2023Review
- Long-term effects of asthma medication on asthma symptoms: an application of the targeted maximum likelihood estimation.BMC medical research methodology · 2020Article
- Mechanisms of Particles in Sensitization, Effector Function and Therapy of Allergic Disease.Frontiers in immunology · 2020Review
- Immunoregulatory Effects of Subcutaneous Immunotherapy on Lymphocyte Subgroups and Cytokines in Children with Asthma.Journal of immunology research · 2019Article
- Impact of allergen immunotherapy in allergic asthma.Immunotherapy · 2018Review
- Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children.Frontiers in pediatrics · 2017Review
- Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.Therapeutic advances in respiratory disease · 2017Review
- Allergen-specific immunotherapy in pediatric allergic asthma.Asia Pacific allergy · 2016Review
- Adenosine influences myeloid cells to inhibit aeroallergen sensitization.American journal of physiology. Lung cellular and molecular physiology · 2016Article
- Allergen immunotherapy in asthma; what is new?Asthma research and practice · 2015Review
- Immunosuppression in early postnatal days induces persistent and allergen-specific immune tolerance to asthma in adult mice.PloS one · 2015Article
- Immune mechanisms of sublingual immunotherapy.Current allergy and asthma reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current asthma therapies can effectively control symptoms and the on-going inflammatory process; however, they do not affect the underlying, dysregulated immune response. Thus, they are limited to blunting the progression of the disease, which relapses on ceasing the treatment. Allergen-specific immunotherapy (AIT) is the only etiology-based treatment capable of disease modification. Recent evidence provided a plausible explanation for its multiple mechanisms inducing both rapid desensitization and long-term allergen-specific immune tolerance, as well as the suppression of allergic inflammation in the affected tissues. Although the current guideline documents give both subcutaneous (SCIT) and sublingual (SLIT) immunotherapy a conditional recommendation in allergic asthma due to the moderate and low quality of evidence, respectively, a growing body of evidence from double-blind, placebo-controlled studies shows that both SLIT and SCIT are effective in reducing symptom scores and medication use, improving quality of life, and inducing favorable changes in specific immunologic markers. Due to the very limited evidence from head-to-head comparative studies and variability of the end-point used in different studies, it is currently not possible to assess superiority of either route of vaccine administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.